



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cell Line

Description

Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line is a Raji cell line in which CD19 (Cluster of Differentiation 19, B lymphocyte surface antigen B4, or CVID3) and CD20 (B-lymphocyte antigen CD20, or MS4A1) have been genetically removed from Raji cells using CRISPR/Cas9 genome editing, while also constitutively expressing firefly (*Photinus pyralis*) luciferase under the control of a CMV promoter. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD19/CD20 Double Knockout Raji Cell Line (BPS Bioscience #82623).

This cell line has been validated by genome sequencing, flow cytometry and luciferase activity measurement.

Background

The Raji cell line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T or CAR NK cells.

CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed on the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy. CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B-cell malignancies, including B-cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B-cell populations and manage B-cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.

Firefly luciferase has been used as a sensitive reporter to study a wide range of biological responses. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cells killing upon co-culture with CAR-T or NK cells.

Application

- Use as control in CAR-T or NK co-culture killing assays
- *In vitro* and *in vivo* Bioluminescence Imaging

Materials Provided

Components	Format
2 vials of frozen cells	Each vial contains >1 x 10 ⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Parental Cell Line

Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Materials Required but Not Supplied



These materials are not supplied with the cell line but are necessary for cell culture and cellular assays. BPS Bioscience's reagents are validated and optimized for use with this cell line and are highly recommended for best results. Media components are provided in the Media Formulations section below.

Media Required for Cell Culture

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184
Growth Medium 2D	BPS Bioscience #79639

Materials Required for Cellular Assay

Name	Ordering Information
Thaw Medium 2	Bioscience #60184
96-well Tissue Culture-treated White Clear-bottom Assay Plate	Corning #3610
ONE-Step™ Luciferase Assay System	BPS Bioscience #60690
Luminometer	

Storage Conditions



Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Media Formulations

For best results, the use of validated and optimized media from BPS Bioscience is *highly recommended*. Other preparations or formulations of media may result in suboptimal performance.



Note: Thaw Media do *not* contain selective antibiotics. However, Growth Media *do* contain selective antibiotics, which are used to maintain selective pressure on the cell population expressing the gene of interest. Cells should be grown at 37 °C with 5% CO₂. BPS Bioscience's cell lines are stable for at least 10 passages when grown under proper conditions.

Media Required for Cell Culture

Thaw Medium 2 (BPS Bioscience #60184):

RPMI-1640 (ATCC modification) medium supplemented with 10% FBS, 1% Penicillin/Streptomycin.

Growth Medium 2D (BPS Bioscience #79639):

RPMI-1640 (ATCC modification) medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 200 µg/ml of Hygromycin B.

Cell Culture Protocol

Note: Raji cells are derived from human material and thus the use of adequate safety precautions is recommended.

Cell Thawing

1. Swirl the vial of frozen cells for approximately 60 seconds in a 37°C water bath. As soon as the cells are thawed (it may be slightly faster or slower than 60 seconds), quickly transfer the entire contents of the vial to a tube containing 10 ml of pre-warmed Thaw Medium 2.

Note: Leaving the cells in the water bath at 37°C for too long will result in rapid loss of viability.

2. Immediately spin down the cells at 300 x *g* for 5 minutes, remove the medium and resuspend the cells in 5 ml of pre-warmed Thaw Medium 2.
3. Transfer the resuspended cells to a T25 flask and incubate at 37°C in a 5% CO₂ incubator.
4. After 24 hours of culture, check for cell viability. For a T25 flask, add 3-4 ml of Thaw Medium 2, and continue growing in a 5% CO₂ incubator at 37°C until the cells are ready to passage.
5. Cells should be passaged before they reach a density of 2 x 10⁶. At first passage and subsequent passages, use Growth Medium 2D.

Cell Passage

Dilute the cell suspension into new culture vessels at a minimum of 0.2 x 10⁶ cells/ml in Growth Medium 2D. The recommended sub-cultivation ratio is 1:6 to 1:8 once or twice per week, so cells are maintained between 0.2 x 10⁶ cells/ml and 2 x 10⁶ cells/ml.

Cell Freezing

1. Spin down the cells at 300 x *g* for 5 minutes, remove the medium and resuspend the cell pellet in 4°C Cell Freezing Medium (BPS Bioscience #79796) at a density of ~2 x 10⁶ cells/ml.
2. Dispense 1 ml of cell suspension into each cryogenic vial. Place the vials in an insulated container for slow cooling and store at -80°C overnight.
3. Transfer the vials to liquid nitrogen the next day for long term storage.



Note: It is recommended to expand the cells and freeze at least 10 vials at an early passage for future use.

A. Validation Data




Figure 1. Genomic sequencing of CD19 in the Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line. Genomic DNA from the CD19/CD20 Double Knockout Raji cells was isolated and sequenced. CD19/CD20 Double Knockout Raji Cell Line (#82623) was used as the parental cell line. The PAM (Protospacer Adjacent Motif) is shown in maroon, the sgRNA (synthetic guide RNA) is shown in green, and the Indels (Insertions/Deletions) in the two CD19 alleles are highlighted in red. The CD19 genomic DNA is labeled as gDNA.



Figure 2. Genomic sequencing of CD20 in the Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line. Genomic DNA from the CD19/CD20 Double Knockout Raji cells was isolated and sequenced. CD19/CD20 Double Knockout Raji Cell Line (#82623) was used as the parental cell line. The PAM (Protospacer Adjacent Motif) is shown in blue, the sgRNA (synthetic guide RNA) is shown in green, and the Indels (Insertions/Deletions) in the two CD20 alleles are highlighted in red. The CD20 genomic DNA is labeled as gDNA.




Figure 3. CD19 expression in Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line by flow cytometry.

Cells were stained with Anti-CD19 Antibody, PE-Labeled (#101625) and analyzed by flow cytometry. Parental Raji cells are shown in blue, unstained parental Raji cells are shown in red, and Firefly Luciferase CD19/CD20 Double Knockout Raji cells are shown in green. The y axis shows the % of cells, while the x axis represents the fluorophore intensity.




Figure 4. CD20 Expression in Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line by flow cytometry.

Cells were stained with PE Anti-CD20 antibody [2H7] (Abcam #AB112461) and analyzed by flow cytometry. Parental Raji cells are shown in blue, unstained parental Raji cells are shown in red, and the Firefly Luciferase CD19/CD20 Double Knockout Raji cells are shown in green. The y axis shows the % of cells, while the x axis represents the fluorophore intensity.




Figure 5. Luciferase activity in Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line. Firefly Luciferase CD19/CD20 Double Knockout Raji cells and parental Raji cells were seeded into a 96-well plate at 5000 cells/well in 50 μ l of Thaw Medium 2, and the luciferase activity was measured using the ONE-Step™ Luciferase Assay System (#60690).

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.

License Disclosure

Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide

Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

Related Products

Products	Catalog #	Size
Firefly Luciferase/CD20 Double Knockout Raji Cell Line	82624	2 vials
Anti-CD20 CAR-T Cells	78611	1 vial
Anti- CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3 ζ)	78606	50 μ l
Anti-CD20 Functional Antibody	71209	100 μ g
CD20 Knockout Raji Cell Line	82622	2 vials
CD19/CD20 Double Knockout Raji Cell Line	82623	2 vials

Version 091624